CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Empagliflozin 25 MG +1 moredrug
Likely dose
Empagliflozin 25 mg orally once dailyAI-extracted
Key inclusion· 2
  • ✓eGFR >60 ml/min
  • ✓Healthy volunteers or type 2 diabetes patients who are otherwise healthy
Key exclusion· 6
  • ✕eGFR <60 ml/min
  • ✕Type 2 diabetes patients on insulin
  • ✕Type 2 diabetes patients on GLP-1 RA
  • ✕Type 2 diabetes patients on SGLT2 inhibitor treatment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03193684
NCT03193684Phase 4Completed
CompareCT.gov

Effect of Empagliflozin on Hepatic Glucose Metabolism: Role of Autonomic Nervous System

The University of Texas Health Science Center at San Antonio·interventional·Posted Jun 21, 2017·Updated Aug 28, 2024

In Brief

A Phase 4 clinical trial evaluating Empagliflozin 25 MG and Control for Hepatic Glucose Metabolism. Completed, enrolled 72 participants across 1 site.

Detailed Summary

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Glucose Metabolism
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJun 21, 2017
Enrollment StartMay 20, 2018
Primary CompletionJan 30, 2023
Study CompletionJan 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.0 years ago

Interventions

Empagliflozin 25 MGdrug

subjects will receive daily dose of 25mg of empagliflozin for 3 months

Controldrug

Placebo